Cancer clinical trials in the region Provence-Alpes-Côte d'Azur
442 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 3
Stomach and esophageal cancer
#NCT06644781
#2023-509630-19-00
Required histologic types
Esophagus
Required histologic sub types
Squamous cell carcinoma
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Immunotherapy
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
12 recruiting sites
Daiichi Sankyo
Phase 3
Breast cancer
#NCT06492616
#2024-515445-42-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Surgery
20 recruiting sites
Stemline Therapeutics, Inc.
Phase 3
Chronic myeloid leukemia (CML)
#NCT06423911
#2024-511495-32-00
Partie B (Mutation T315I)
Required disease stage
Chronic phase
Required genetic anomalies
T315I
Required number of previous lines of therapy
1
2
3 or more
Required previous treatments
ATP pocket inhibitor
Allosteric inhibitor
Excluded previous treatments
Systemic Treatment-Naive
5 recruiting sites
Ascentage Pharma Group Inc.
Phase 3
Chronic myeloid leukemia (CML)
#NCT06423911
#2024-511495-32-00
Partie A (Non-T315I)
Required disease stage
Chronic phase
Required number of previous lines of therapy
2
3 or more
Required previous treatments
ATP pocket inhibitor
Allosteric inhibitor
Excluded genetic anomalies
T315I
Excluded previous treatments
Systemic Treatment-Naive
5 recruiting sites
Ascentage Pharma Group Inc.
Phase 3
Colon cancer
Rectal cancer
#NCT06107920
#2024-516456-17-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Localized
Required genetic anomalies
MSS/pMMR
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Surgery
Chemotherapy
Radiotherapy
28 recruiting sites
Hôpital universitaire de Rouen
Phase 3
Lung cancer
#NCT07291037
#2024-520101-39-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Non-squamous NSCLC
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
Required previous treatments at advanced or metastatic stage
Immunotherapy
Chemotherapy
Excluded genetic anomalies
ALK
EGFR
HER2
KRAS G12C
MET
NTRK-1/2/3
RET
ROS-1
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
AstraZeneca
Phase 3
Sarcoma and GIST
#NCT04307277
#2024-515384-62-00
Required histologic types
Soft tissue sarcoma
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Surgery
Required sarcoma grades
Grade 1
Grade 2
Grade 3
20 recruiting sites
Institut Claudius Regaud
Phase 3
Lung cancer
#NCT07218146
#2025-522818-23-00
Required histologic types
SCLC (Small Cell Lung Cancer)
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
Required previous treatments at localized stage
Chemotherapy
Bispecific T-cell engager antibodies
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Chemotherapy
Bispecific T-cell engager antibodies
13 recruiting sites
Zai Lab (Shanghai) Co., Ltd
Phase 3
Lung cancer
#NCT07365241
#2025-523819-11-00
Required histologic types
SCLC (Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
Required previous treatments at advanced or metastatic stage
Immunotherapy
Chemotherapy
Bispecific T-cell engager antibodies
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Antibody Drug Conjugates (ADC)
1 recruiting site
Abbvie
Phase 3
Lung cancer
#NCT06170788
#2023-503376-24-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Metastatic
Required PDL1 statuses
PDL1 Positive (>= 50%)
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
8 recruiting sites
Merck Sharp & Dohme LLC